Stay updated on Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the results of a Phase II trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer. This change may reflect new data or findings related to the impact of immune checkpoint therapy on patients with anaplastic thyroid cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:33.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    45%
    Check dated 2024-05-22T21:30:28.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:41:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.